Genetics - Recording a family history
Dr John Spicer and Dr Imran Rafi explain how to create a genetic map. Read more
The discovery that the drug amiloride, a potassium-sparing diuretic, can reduce the degeneration of nerve tissue offers fresh hope for MS sufferers.
The researchers hypothesised that the acid-sensing ion channel (ASIC1) plays a role in the development of MS.
ASIC1 works by gauging acid levels around the cell and fluxes sodium and calcium molecules into and out of cells accordingly. This function is an important part of the process of sensing pain and touch.
Using mice with a condition that mimics some aspects of the human form of MS, the researchers found that the ASIC1 channel contributes to degeneration of the nerve axon.
The next step was to identify drugs that could target the ASIC1 channel.
The heart failure drug amiloride is a known ASIC1 antagonist. MS mice were injected daily with amiloride for a number of weeks.
Those injected with the drug showed reduced axonal degeneration compared with mice that had not been injected.
Lead researcher Professor Lars Fugger, of the Medical Research Council human immunology unit at the University of Oxford, said: 'When sodium and calcium levels accumulate in excessive proportions within nerve cells the axon becomes damaged. We found this damage was reduced in mice given amiloride. The drug works by blocking the action of the channel that lets sodium and calcium molecules into the cell.'
Using established drugs in new ways is cheaper than starting the discovery process from scratch, added Professor Fugger.
The research team is planning a clinical trial that will aim to find out if amiloride is beneficial in treating MS in humans.
Comment below and tell us what you think
Quick search - use * for an abbreviated search, eg nico*
Dr John Spicer and Dr Imran Rafi explain how to create a genetic map. Read more
An apology and sympathy can go a long way to resolving a grievance, explains the MDDUS's medico-lega... Read more
Play out the doctor, patient and assessor roles in a study group or plan on your own how you would a... Read more
Contributed by Mr Antonio V Antoniou, consultant gynaecologist and lead in minimal access surgery an... Read more
Dr Mark Ritchie, GPSI in pain management, Morriston, Swansea Read more
Contributed by Dr Mark Ritchie, GPSI in pain management, Morriston, Swansea Read more
Janssen-Cilag has launched Stelara for the treatment of moderate to severe plaque psoriasis where ot... Read more
Nicorette Invisipatch is the latest addition to the range of available nicotine replacement therapy ... Read more
Flamasacard, a prolonged-release formulation of aspirin, for secondary prophylaxis after a first cor... Read more
Comments
Only registered users may comment. Log in now or register for a free account.
There are problems with your form submission.
Please review the errors shown below.